Page last updated: 2024-09-05

sorafenib and carfilzomib

sorafenib has been researched along with carfilzomib in 2 studies

Compound Research Comparison

Studies (sorafenib)	Trials (sorafenib)	Recent Studies (post-2010) (sorafenib)	Studies (carfilzomib)	Trials (carfilzomib)	Recent Studies (post-2010) (carfilzomib)
6,520	730	5,251	748	121	716

Protein Interaction Comparison

Protein	Taxonomy	carfilzomib (IC50)
Proteasome subunit beta type-11	Homo sapiens (human)	0.0608
26S proteasome non-ATPase regulatory subunit 11	Homo sapiens (human)	0.0086
26S proteasome non-ATPase regulatory subunit 12	Homo sapiens (human)	0.0086
26S proteasome non-ATPase regulatory subunit 14	Homo sapiens (human)	0.0086
Proteasome subunit alpha type-7	Homo sapiens (human)	0.0608
26S proteasome non-ATPase regulatory subunit 3	Homo sapiens (human)	0.0086
26S proteasome regulatory subunit 6A	Homo sapiens (human)	0.0086
Proteasome subunit beta type-1	Homo sapiens (human)	0.5937
Proteasome subunit alpha type-1	Homo sapiens (human)	0.0608
Proteasome subunit alpha type-2	Homo sapiens (human)	0.0608
Proteasome subunit alpha type-3	Homo sapiens (human)	0.0608
Proteasome subunit alpha type-4	Homo sapiens (human)	0.0608
Proteasome subunit beta type-8	Homo sapiens (human)	0.0407
Proteasome subunit beta type-9	Homo sapiens (human)	0.7166
Proteasome subunit alpha type-5	Homo sapiens (human)	0.0608
Proteasome subunit beta type-4	Homo sapiens (human)	0.0608
Proteasome subunit beta type-6	Homo sapiens (human)	0.199
Proteasome subunit beta type-5	Homo sapiens (human)	0.0237
26S proteasome regulatory subunit 7	Homo sapiens (human)	0.0086
Proteasome subunit beta type-10	Homo sapiens (human)	0.1339
26S proteasome regulatory subunit 6B	Homo sapiens (human)	0.0086
26S proteasome non-ATPase regulatory subunit 8	Homo sapiens (human)	0.0086
Proteasome subunit beta type-3	Homo sapiens (human)	0.0608
Proteasome subunit beta type-2	Homo sapiens (human)	0.7493
26S proteasome non-ATPase regulatory subunit 7	Homo sapiens (human)	0.0086
26S proteasome non-ATPase regulatory subunit 4	Homo sapiens (human)	0.0086
26S proteasome complex subunit SEM1	Homo sapiens (human)	0.0086
Proteasome subunit alpha type-6	Homo sapiens (human)	0.0608
26S proteasome regulatory subunit 4	Homo sapiens (human)	0.0086
26S proteasome regulatory subunit 8	Homo sapiens (human)	0.0086
26S proteasome regulatory subunit 10B	Homo sapiens (human)	0.0086
Glutathione S-transferase omega-1	Homo sapiens (human)	0.15
26S proteasome non-ATPase regulatory subunit 2	Homo sapiens (human)	0.0086
26S proteasome non-ATPase regulatory subunit 6	Homo sapiens (human)	0.0086
Proteasomal ubiquitin receptor ADRM1	Homo sapiens (human)	0.0086
Proteasome subunit alpha-type 8	Homo sapiens (human)	0.0608
Proteasome subunit beta type-7	Homo sapiens (human)	0.0578
26S proteasome non-ATPase regulatory subunit 1	Homo sapiens (human)	0.0086
26S proteasome non-ATPase regulatory subunit 13	Homo sapiens (human)	0.0086

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
Jiang, C; Li, XX; Wang, HY; Xu, R; Xu, XY; Yang, Y; Zheng, XFS; Zhou, YF	1

Other Studies

2 other study(ies) available for sorafenib and carfilzomib

Article	Year
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013
Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma. Molecular cancer therapeutics, 2018, Volume: 17, Issue:12 Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Endoplasmic Reticulum Stress; Epithelial-Mesenchymal Transition; Female; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Oligopeptides; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays	2018

Article

Year

Identification of potent Yes1 kinase inhibitors using a library screening approach.

Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013

Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma.

Molecular cancer therapeutics, 2018, Volume: 17, Issue:12

Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Endoplasmic Reticulum Stress; Epithelial-Mesenchymal Transition; Female; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Oligopeptides; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays

2018